NGC Update Service: May 22, 2017


May 22, 2017

New This Week

Guideline Summaries

American Gastroenterological Association Institute

Brain Trauma Foundation

Eastern Association for the Surgery of Trauma

Institute for Clinical Systems Improvement

Program in Evidence-based Care

Withdrawn Guideline Summaries

The guideline summary listed below has been withdrawn from the NGC Web site because it no longer meets the NGC Inclusion Criteria. See the Guideline Summaries Archive for a complete list of summaries that have been withdrawn from NGC.

Society for Integrative Oncology

  • Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer.


Conference News

G-I-N NA Webinar Series: USPSTF Methods for Making Recommendations for Diverse Populations:

When: May 30, 2017 12:30PM ET (11:30PM CT; 10:30AM MT; 9:30AM PT)


The U.S. Preventive Services Task Force (USPSTF) makes evidence-based recommendations on clinical preventive services for primary care clinicians and their patients. The Evidence-based Practice Centers (EPCs) support the USPSTF with systematic reviews that are used as the basis for the recommendations. Hear what one EPC and the USPSTF have done to improve recommendations for diverse populations.

Kirsten Bibbins-Domingo, MD, PhD, Professor of Medicine, UCSF and Immediate Past Chair, USPSTF
Jennifer S. Lin, MD, MCR, Director, Kaiser Permanente Research Affiliates EPC
Michelle Eder, PhD, Co-Director, USPSTF Scientific Resource Center

Objectives: By the end of the webinar you will be able to:

  1. State methods of synthesizing evidence on subpopulations.
  2. Apply evidence on diverse populations to the development of recommendations on clinical preventive services.

For more information contact: Mary Nix at

U.S. FDA Advisory

May 16, 2017: Canagliflozin (Invokana, Invokamet): Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

AHRQ Announces Grant Opportunities to Implement Evidence-Based Findings into CDS

The Division of Health IT recently released two Funding Opportunity Announcements as part of AHRQ's Patient-Centered Outcomes Research (PCOR) Clinical Decision Support (CDS) Initiative to accelerate evidence into practice through CDS.

Health Awareness Topics: May 2017

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.

Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).